Latest News

BOSTON – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced Health Canada has granted Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation....
OTTAWA, Canada — Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that Health Canada has granted a marketing authorization for ANDEMBRY® (garadacimab) for routine prevention of attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ANDEMBRY is a monoclonal antibody designed to target activated FXII (FXIIa),...
Charlottesville, VA – Could healthy fats found in nuts and fish slow the progression of potentially deadly lung scarring known as pulmonary fibrosis and delay the need for lung transplants? UVA pulmonary researchers looked at the association between blood-plasma levels of omega-3 fatty acids – the heart-healthy fats found in...
Vienna, Austria – At least 75 per cent of type 2 diabetes cases could be avoided by adopting a healthy lifestyle. A plant-based diet has been shown to play a key role in this. With limitations – as demonstrated in a study led by Tilman Kühn from MedUni Vienna’s Center...
A new partnership combining AI and rare disease drug discovery with a patient-centered treatment network is seeking to unlock drug cures for the world’s most intractable diseases. AI-powered, patient-inspired technology company Healx – which is headquartered on Hills Road – has teamed up with US-based Mission: Cure, a non-profit coalition...
Odense, Denmark – People who are hard of hearing spend more energy listening. That energy comes at the expense of other cognitive functions. Cognitive functions are the mental processes in the brain that enable us to think and solve problems, among other things. In a new study featuring data from...
Heidelberg, Germany – A new pharmacological inhibitor can intervene in a central cell death mechanism that is responsible for the death of motor neurons and hence important for the progression of the motor neuron disease amyotrophic lateral sclerosis (ALS). A research team led by Prof. Dr Hilmar Bading, neurobiologist at...
NEWTOWN, Pa. — Helius Medical Technologies, Inc. (NASDAQ: HSDT) is expanding its presence at the 2024 American Physical Therapy Association (APTA) Combined Sections Meeting (CSM), that will be held February 15 through February 17 at the Boston Convention and Exposition Center: In addition to exhibiting its innovative Portable Neuromodulation Stimulator...